Somatostatin receptor imaging finds tumours that carry somatostatin receptors on their surface, above all neuroendocrine tumours of the pancreas, gut and lung. A tracer that binds to these receptors is injected and the body is scanned. The modern form is gallium-68 DOTATATE (or DOTATOC) PET-CT; the older form is the indium-111 octreotide scan.
It locates primary tumours and spread that ordinary CT and MRI can miss and shows whether a tumour could respond to receptor-targeted treatment. Fast-growing, poorly differentiated tumours often lose these receptors and may not show up.
What Somatostatin Receptor Imaging (Ga-68 DOTATATE PET-CT and Octreotide Scan) shows
The scan maps every site with a high density of somatostatin receptors. In practice it answers four questions: where the primary neuroendocrine tumour is when only metastases have been found; how far the disease has spread to liver, lymph nodes and bone; whether uptake is strong enough to make you eligible for peptide receptor radionuclide therapy (PRRT) with lutetium-177; and whether disease has returned after surgery. It also images meningiomas, paragangliomas, phaeochromocytomas and medullary thyroid cancer. Normal uptake in the spleen, kidneys, pituitary and adrenal glands is expected and not a sign of disease.
When Somatostatin Receptor Imaging (Ga-68 DOTATATE PET-CT and Octreotide Scan) is recommended
- A confirmed or suspected neuroendocrine tumour needing staging before surgery
- Raised chromogranin A or hormone syndromes such as carcinoid flushing with no tumour found on CT
- Selection and planning for lutetium-177 PRRT
- Follow-up after treatment when recurrence is suspected
- Planning radiotherapy for meningioma near critical structures
Limits and situations where another test is better:
- High-grade neuroendocrine carcinomas, which are better imaged with FDG PET-CT; some patients need both
- Insulinomas, many of which have few somatostatin receptors and need other tracers or endoscopic ultrasound
- Pregnancy
- General cancer screening, where it has no role
How to prepare
- Long-acting octreotide or lanreotide injections: the scan is usually timed just before your next dose, around 3 to 4 weeks after the last
- Short-acting octreotide is typically paused for 24 hours if your symptoms allow
- No fasting is needed for the PET-CT; drink water freely
- Bring previous scans, pathology reports with Ki-67 grade and your injection dates
What happens during the test
For Ga-68 PET-CT the tracer is injected into a vein, you rest for 45 to 60 minutes, and the scan from skull to thigh takes about 20 to 30 minutes. The whole visit is around 2 hours. The older octreotide scan needs imaging at 4 and 24 hours, sometimes 48, so it spans two or three days. Neither causes any sensation.
Results and next steps
A nuclear medicine physician reports within 1 to 3 working days, often scoring uptake against the liver (Krenning score). The result should be discussed at a neuroendocrine tumour board together with pathology grade, to choose between surgery, somatostatin analogues, PRRT, targeted drugs or observation.
- Test time: About 2 hours (PET-CT); 2 to 3 days (octreotide scan)
- Results ready: 1 to 3 working days
- Back to everyday activity: None
Safety and risks
- Radiation dose similar to a diagnostic CT, lower with Ga-68 PET than with the octreotide scan
- False positives from inflammation, the pancreatic head and benign lesions
- False negatives in small or receptor-poor tumours
- Brief limits on close contact with infants for the rest of the day
Arranging Somatostatin Receptor Imaging (Ga-68 DOTATATE PET-CT and Octreotide Scan) in Türkiye
Gallium-68 tracers are made on site from a generator and are not available in every country, so travelling for this scan is reasonable, especially when it is combined with a specialist opinion or leads directly into PRRT planning. A visit of 3 to 4 days is usually enough for the scan, report and consultation.
Send your previous reports and the question you want answered and a Clinic-Y coordinator replies within 24 hours with suitable teams and written, all-inclusive proposals side by side. Reviewing your case is free.
الأسئلة المتكررة
Is DOTATATE PET better than an octreotide scan?
Yes. It detects smaller lesions, takes two hours instead of two days and gives a lower radiation dose. Choose it where available.
Do I have to stop my lanreotide or octreotide?
Not the long-acting injection; the scan is simply timed towards the end of the dosing interval. Never stop treatment without your oncologist's advice.
Does a positive scan mean I can have PRRT?
It is one requirement. Kidney function, blood counts, tumour grade and disease progression also decide eligibility.